We focused thesestudies on the Myelin Oligodendrocyte Glycoprotein peptide (pMOG35-55)-induced model of experimental autoimmune encephalomyelitis (EAE) in B6 mice, where pMOG38-49/I-Ab-NP therapy can reverse established disease by inducing the formation and expansion of cognate TR1 cells (7, 10). The gene discussed is MOG; the disease is experimental autoimmune encephalomyelitis.